NASDAQ$EVLO
Evelo Biosciences Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Reported financial results for the second quarter of 2021
Evelo Biosciences reported a net loss of $31.6 million for the second quarter of 2021, with cash and cash equivalents totaling $123.3 million as of June 30, 2021. The company is advancing its clinical development programs, including EDP1815 in psoriasis and atopic dermatitis, and expects multiple clinical data readouts over the next 6-12 months.
- EDP1815 Phase 2b data in psoriasis is expected in 3Q 2021.
- Finalized design of Phase 2 clinical trial of EDP1815 in atopic dermatitis; start of trial anticipated in 3Q 2021.
- Mark Plinio was appointed as Chief Commercial Officer.
- Multiple clinical data readouts are expected over the next 6-12 months.
Headline financials
Revenue & EPS history
Evelo · Revenue · Quarterly
$0
Forward guidance
Evelo anticipates data from the Phase 2b dose-ranging trial and Phase 1b cohorts with tablets and capsules for EDP1815 in psoriasis to be reported in 3Q 2021. The company also expects to start the Phase 2 trial for EDP1815 in atopic dermatitis in 3Q 2021, with data anticipated in 3Q 2022. Interim data from the Phase 1b trial for EDP1867 in atopic dermatitis is expected in 4Q 2021. Clinical development for EDP2939 in inflammation and EDP1908 in oncology is planned to be initiated in 2022.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2021
+1.3%
Avg return
Earnings day
-1.4%
Avg return
5 days after
-9.7%
Avg return
30 days after
54%
13 / 24 earnings
Positive
+32.3%
Q2 2023
Best reaction
-20.3%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2023 | +0.0% | +0.0% | -9.8% | |
| Q3 2023 | -7.6% | +4.5% | +3.8% | |
| Q2 2023 | +32.3% | -30.5% | -41.0% | |
| Q1 2023 | +2.9% | +10.2% | -28.8% | |
| Q4 2022 | -17.8% | -27.0% | -46.9% | |
| Q3 2022 | +3.3% | -3.3% | -8.5% | |
| Q2 2022 | -7.1% | -10.5% | -25.4% | |
| Q1 2022 | -20.3% | -14.5% | -2.4% | |
| Q4 2021 | +29.4% | +13.5% | -26.3% | |
| Q3 2021 | +10.2% | +27.0% | +6.0% | |
| Q2 2021 | -0.9% | +5.0% | +20.7% | |
| Q1 2021 | +8.8% | -14.4% | +11.0% | |
| Q4 2020 | +14.5% | +21.2% | +1.6% | |
| Q3 2020 | -12.9% | -5.9% | +14.0% | |
| Q2 2020 | -1.6% | -0.5% | +15.2% | |
| Q1 2020 | -5.7% | -14.0% | -20.9% | |
| Q4 2019 | +1.8% | +12.2% | -28.4% | |
| Q3 2019 | -3.3% | -6.1% | -35.9% | |
| Q2 2019 | +3.9% | -2.2% | +7.0% | |
| Q1 2019 | +0.8% | -1.5% | -11.8% | |
| Q4 2018 | +1.3% | +3.0% | -6.9% | |
| Q3 2018 | +0.2% | +3.4% | +3.7% | |
| Q2 2018 | -3.4% | -5.9% | +2.6% | |
| Q1 2018 | +1.8% | +2.2% | -24.8% | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro